Re: BMY
It's still going to be an uphill battle even with EFS.
Stage I and II do not need neo-adjuvant and surgeons are concerned about getting the patient into surgery asap. For stage III, it's a nice benefit, likely better value proposition vs. adjuvant atezo for a year, even for PD-L1 50%+ which is where atezo's benefit really is right now. Remains to be seen how competitive this is vs. adjuvant pembro. But it's not going to be a big money maker, since neo-adjuvant is just 3 cycles. Now if they can prove that the optimal strategy is to use opdivo+chemo as neo-adj and then follow with opdivo mono for up to a year as adjuvant, that would be a money-maker. But again, anything that starts as neo-adj will be limited to stage III disease even if you generate data in Stage I and II - earlier stages don't need debulking and are rushed into surgery right away.
